易位蛋白总分布容积与未治疗重性抑郁障碍病程的相关性:横断面研究
该横断面研究纳入51例当前重性抑郁发作患者和30名健康对照,用18F-FEPPA PET测量三个主要灰质脑区的TSPO总分布容积(VT)。未治疗重性抑郁障碍病程、总病程和抗抑郁药暴露时长均显著预测TSPO VT,三者合计解释约50%的VT变异;未治疗≥10年者三个脑区VT较未治疗≤9年者高29-33%,较健康对照高31-39%。
要点
- 未治疗重性抑郁障碍病程是TSPO VT的强预测因子(p<0·0001)。
- 未治疗≥10年者前额叶皮质、前扣带回和岛叶TSPO VT较未治疗≤9年者高29-33%。
- 长期未治疗者三个主要灰质脑区TSPO VT较健康对照高31-39%(p=0·00047)。
核心结论
- 未治疗重性抑郁障碍病程越长,小胶质细胞活化标志物TSPO VT越高,提示疾病可能进入不同阶段。
- 给予抗抑郁药治疗后,小胶质细胞活化的年增长不再明显。
研究设计与样本
- 横断面研究,2009年9月1日至2017年7月6日从加拿大多伦多地区及成瘾与精神健康中心招募18-75岁参与者。
- 筛查134人,纳入81人(当前重性抑郁发作51例,健康对照30例),分析时排除1例用药信息不可靠的抑郁发作患者。
- 采用18F-FEPPA PET测量前额叶皮质、前扣带回和岛叶三个主要灰质感兴趣区及12个附加区域的TSPO VT。
主要发现
- 未治疗重性抑郁障碍病程显著预测TSPO VT(p<0·0001)。
- 总病程(p=0·0021)和抗抑郁药暴露时长(p=0·037)也显著预测TSPO VT。
- 上述预测因子合计解释前额叶皮质、前扣带回和岛叶TSPO VT约50%的变异。
- 未治疗≥10年者三个脑区TSPO VT较未治疗≤9年者高29-33%。
- 长期未治疗者三个主要灰质脑区TSPO VT较健康对照高31-39%(p=0·00047)。
关键数值与推荐
- 抑郁发作患者需17项汉密尔顿抑郁量表评分≥17。
- 入组时需未用药或PET扫描前至少4周维持稳定剂量药物。
- 排除近6个月内接受脑刺激治疗、近1个月内使用抗炎药≥1周、有精神病性症状、双相障碍或妊娠哺乳者。
临床怎么用
- 对重性抑郁障碍应尽早启动有效治疗,减少未治疗病程,可能有助于减轻小胶质细胞活化相关神经进展。
- TSPO VT可作为研究小胶质细胞活化的影像标志物,但目前尚不能作为临床常规检测。
局限性
- 横断面设计无法确立因果关系。
- 样本量有限(抑郁发作51例、健康对照30例),分析时排除1例。
- 排除标准较多(如精神病性症状、双相障碍、吸烟、物质依赖等),限制结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with major depressive disorder frequently exhibit increasing persistence of major depressive episodes. However, evidence for neuroprogression (ie, increasing brain pathology with longer duration of illness) is scarce. Microglial activation, which is an important component of neuroinflammation, is implicated in neuroprogression. We examined the relationship of translocator protein (TSPO) total distribution volume (VT), a marker of microglial activation, with duration of untreated major depressive disorder, and with total illness duration and antidepressant exposure. METHODS: In this cross-sectional study, we recruited participants aged 18-75 years from the Toronto area and the Centre for Addiction and Mental Health (Toronto, ON, Canada). Participants either had major depressive episodes secondary to major depressive disorder or were healthy, as confirmed with a structured clinical interview and consultation with a study psychiatrist. To be enrolled, participants with major depressive episodes had to score a minimum of 17 on the 17-item Hamilton Depression Rating Scale, and had to be medication free or taking a stable dose of medication for at least 4 weeks before PET scanning. Eligible participants were non-smokers; had no history of or concurrent alcohol or substance dependence, neurological illness, autoimmune disorder, or severe medical problems; and were free from acute medical illnesses for the previous 2 weeks before PET scanning. Participants were excluded if they had used brain stimulation treatments within the 6 months before scanning, had used anti-inflammatory drugs lasting at least 1 week within the past month, were taking hormone replacement therapy, had psychotic symptoms, had bipolar disorder (type I or II) or borderline antisocial personality disorder, or were pregnant or breastfeeding. We scanned three primary grey-matter regions of interest (prefrontal cortex, anterior cingulate cortex, and insula) and 12 additional regions and subregions using 18F-FEPPA PET to measure TSPO VT. We investigated the duration of untreated major depressive disorder, and the combination of total duration of disease and duration of antidepressant treatment, as predictor variables of TSPO VT, assessing their significance. FINDINGS: Between Sept 1, 2009, and July 6, 2017, we screened 134 participants for eligibility, of whom 81 were included in the study (current major depressive episode n=51, healthy n=30). We excluded one participant with a major depressive episode from the analysis because of unreliable information about previous medication use. Duration of untreated major depressive disorder was a strong predictor of TSPO VT (p<0·0001), as were total illness duration (p=0·0021) and duration of antidepressant exposure (p=0·037). The combination of these predictors accounted for about 50% of variance in TSPO VT in the prefrontal cortex, anterior cingulate cortex, and insula. In participants who had untreated major depressive disorder for 10 years or longer, TSPO VT was 29-33% greater in the prefrontal cortex, anterior cingulate cortex, and insula than in participants who were untreated for 9 years or less. TSPO VT was also 31-39% greater in the three primary grey-matter regions of participants with long duration of untreated major depressive disorder compared with healthy participants (p=0·00047). INTERPRETATION: Microglial activation, as shown by TSPO VT, is greater in patients with chronologically advanced major depressive disorder with long periods of no antidepressant treatment than in patients with major depressive disorder with short periods of no antidepressant treatment, which is strongly suggestive of a different illness phase. Consistent with this, the yearly increase in microglial activation is no longer evident when antidepressant treatment is given. FUNDING: Canadian Institutes of Health Research and Neuroscience Catalyst Fund.
引用
- Setiawan E, Attwells S, Wilson AA, et al. Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry. 2018. PMID: 29496589. doi:10.1016/S2215-0366(18)30048-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。